Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC [Phase 2]
This Phase 2 neoadjuvant trial evaluates darolutamide alone or with standard therapy in AR-positive stage II-IIIA breast cancer, including t…
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) [Phase 3]
The Phase 3 KEYNOTE-522 trial evaluating pembrolizumab with chemotherapy as neoadjuvant therapy and pembrolizumab as adjuvant therapy in tri…
-
CLINICAL_TRIALS research · 2025-10-29Clinical Trial Update: Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC [NA]
This clinical trial update notes that the LEAN trial from Yale University is actively recruiting to assess whether lifestyle, exercise, and …
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy [Phase 1]
A Phase 1 trial evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy for patients with advanced cancers; the st…
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer [Phase 2]
STEMVAC is being studied in a Phase 2 trial for early-stage triple-negative breast cancer. The study is currently active but not recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-22Clinical Trial Update: Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients [Phase 2]
Phase 2 clinical trial evaluating anthracycline-free neoadjuvant chemoimmunotherapy for triple-negative breast cancer is currently recruitin…
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) [Phase 1]
First-in-human Phase 1 study of DS-1062a for advanced solid tumors, including breast cancer subtypes and non-small cell lung cancer, is unde…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describing safety, tolerability, and imaging with [68Ga]Ga-DPI-4452 and safety, tolerability, and efficacy…
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors [Phase 1]
This is a completed Phase 1 trial of HMBD-002, a VISTA-targeting monoclonal antibody, as monotherapy and with pembrolizumab in patients with…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas [Phase 1, Phase 2]
Clinical trial update describing a Phase 1/2 study of the monoclonal antibody IMT-009 in various advanced solid tumors and lymphomas, with t…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Sacituzumab Govitecan In TNBC [Phase 2]
Phase 2 study of Sacituzumab Govitecan in triple-negative breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies [Phase 1]
A Phase 1 study of JANX008 in advanced or metastatic solid tumors is currently recruiting, evaluating multiple indications including Non-Sma…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) [Phase 2]
Phase 2 clinical trial update evaluating preoperative pembrolizumab plus radiation therapy in breast cancer, including triple-negative and H…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: Axillary Nodal Burden in HER2+ and TNBC
A completed clinical trial update evaluating axillary nodal burden in HER2-positive and triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer [Phase 2]
A Phase 2 study tested ZEN003694 in combination with talazoparib in triple-negative breast cancer, but the trial was terminated and results …
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC [Phase 2]
A Phase 2 clinical trial investigating neoadjuvant tumor-infiltrating lymphocyte (TIL)– and response-adapted chemoimmunotherapy for triple-n…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors [Phase 2]
Phase 2 clinical trial evaluating atezolizumab in combination with BDB001 and immunogenic radiotherapy for advanced solid tumors is currentl…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
A ClinicalTrials.gov registry entry for NCT02302742 describes a germline mutation carrier registry focused on triple-negative breast cancer …
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) [Phase 1, Phase 2]
This document provides an update on a phase 1/2 trial evaluating cisplatin plus romidepsin and nivolumab for locally recurrent or metastatic…
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial of magrolimab in combination therapy for locally advanced or metastatic triple-negative breast cancer has been terminated and …
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is evaluating infusion of NY-ESO-1–specific TCR-engineered lymphocytes in patients with NY-ESO-1-expressing…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer [Phase 1]
This update notes an ongoing Phase 1 trial evaluating PVX-410 vaccine with pembrolizumab in patients with HLA-A2+ metastatic triple-negative…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer [Phase 1]
Phase 1 clinical trial update evaluating adjuvant PVX-410 vaccine in combination with durvalumab for stage II/III triple-negative breast can…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer [Phase 2]
This Phase 2 trial update describes investigating the combination of radiation therapy, an immunotherapy agent, and a PARP inhibitor for tri…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC) [Phase 2]
This is a Phase II, single-center trial evaluating sacituzumab govitecan in combination with pembrolizumab as neoadjuvant therapy for Stage …